Marker Therapeutics' MT-601 Manufacturing Backed by New CDMO Kincellis Advanced Therapies

Marker Therapeutics Inc. (MRKR) said on Sept. 22, 2026, that its lead program MT-601 (neldaleucel) will gain expanded manufacturing capacity through the formation of Kincellis Advanced Therapies, a U.S.-based cell therapy contract development and manufacturing organization. The company did not disclose financial terms, capacity figures or timelines tied to the arrangement. Kincellis will support production of the MT-601 candidate, which remains Marker's primary clinical asset. The announcement positions the Houston-based biotech to scale manufacturing as it advances MT-601 through development. Shares of MRKR trade on the Nasdaq.